Cohort studies indicating an increased incidence of cancer in immune-suppressed patients or showing that the presence of memory CD4+ Th1 and CTL in tumors is predictive for a beneficial clinical outcome as well as clinical trials in which patients display clinical benefit after adoptive transfer of tumor-specific T cells or after therapeutic vaccination sustain these conclusions [4]. Here, CD4 is linked to neoplasm.